Lexicon Pharmaceuticals Statistics
Total Valuation
LXRX has a market cap or net worth of $497.86 million. The enterprise value is $446.86 million.
Important Dates
The next estimated earnings date is Thursday, March 5, 2026, after market close.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LXRX has 363.40 million shares outstanding. The number of shares has increased by 24.67% in one year.
| Current Share Class | 363.40M |
| Shares Outstanding | 363.40M |
| Shares Change (YoY) | +24.67% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | 1.17% |
| Owned by Institutions (%) | 23.56% |
| Float | 184.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.01 |
| Forward PS | 22.40 |
| PB Ratio | 4.14 |
| P/TBV Ratio | 6.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.64, with a Debt / Equity ratio of 0.54.
| Current Ratio | 5.64 |
| Quick Ratio | 5.45 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.37 |
Financial Efficiency
Return on equity (ROE) is -45.92% and return on invested capital (ROIC) is -14.53%.
| Return on Equity (ROE) | -45.92% |
| Return on Assets (ROA) | -12.94% |
| Return on Invested Capital (ROIC) | -14.53% |
| Return on Capital Employed (ROCE) | -29.62% |
| Revenue Per Employee | $688,000 |
| Profits Per Employee | -$665,796 |
| Employee Count | 103 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 190.96 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +88.29% in the last 52 weeks. The beta is 0.72, so LXRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | +88.29% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 1.07 |
| Relative Strength Index (RSI) | 67.04 |
| Average Volume (20 Days) | 1,714,679 |
Short Selling Information
The latest short interest is 23.66 million, so 6.51% of the outstanding shares have been sold short.
| Short Interest | 23.66M |
| Short Previous Month | 23.34M |
| Short % of Shares Out | 6.51% |
| Short % of Float | 12.86% |
| Short Ratio (days to cover) | 14.21 |
Income Statement
In the last 12 months, LXRX had revenue of $70.86 million and -$68.58 million in losses. Loss per share was -$0.19.
| Revenue | 70.86M |
| Gross Profit | -4.95M |
| Operating Income | -54.57M |
| Pretax Income | -68.58M |
| Net Income | -68.58M |
| EBITDA | -53.94M |
| EBIT | -54.57M |
| Loss Per Share | -$0.19 |
Full Income StatementBalance Sheet
The company has $115.95 million in cash and $64.95 million in debt, with a net cash position of $51.00 million or $0.14 per share.
| Cash & Cash Equivalents | 115.95M |
| Total Debt | 64.95M |
| Net Cash | 51.00M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | 120.16M |
| Book Value Per Share | 0.33 |
| Working Capital | 100.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$72.11 million and capital expenditures -$474,000, giving a free cash flow of -$72.58 million.
| Operating Cash Flow | -72.11M |
| Capital Expenditures | -474,000 |
| Free Cash Flow | -72.58M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
Gross margin is -6.98%, with operating and profit margins of -77.00% and -96.77%.
| Gross Margin | -6.98% |
| Operating Margin | -77.00% |
| Pretax Margin | -96.77% |
| Profit Margin | -96.77% |
| EBITDA Margin | -76.12% |
| EBIT Margin | -77.00% |
| FCF Margin | n/a |
Dividends & Yields
LXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.67% |
| Shareholder Yield | -24.67% |
| Earnings Yield | -13.77% |
| FCF Yield | -14.58% |
Analyst Forecast
The average price target for LXRX is $3.23, which is 135.77% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.23 |
| Price Target Difference | 135.77% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 35.96% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 21, 2015. It was a reverse split with a ratio of 1:7.
| Last Split Date | May 21, 2015 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
LXRX has an Altman Z-Score of -11.25 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.25 |
| Piotroski F-Score | 3 |
